CRHBP and lung adenocarcinoma: Using clinical, transcriptomic, and clinical transcriptomic data, Deng et al. performed a multicategorical prognosis classification of lung adenocarcinoma patients and observed that reduced expression levels of CRHBP were linked with survival without disease progression (PFS, coefficient = − 0.314) and survival with disease (AWD, coefficient = 0.228)20.